immunoglobulin G
immunoglobulin G: sourced relationships with 1 company · 9 clinical trials tracked.
immunoglobulin G evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could immunoglobulin G → ADMA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 2 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ADMA BIOLOGICS, INC. (ADMA) Treatment of Primary Humoral Immunodeficiency (PI) / Primary… | Approved |
Clinical Trial Registry Records (9)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Primary endpoint: Proportion of Participants With a Guillain-Barré Syndrome Disability Scale (GBS-DS) Score ≤2 at Week 4
The Efficacy of Intravenous Immunoglobulin for the Treatment of Bronchopulmonary Dysplasia
Primary endpoint: Diagnosis of bronchopulmonary dysplasia and severity of the condition at 36 weeks of PMA
Post-marketing Database Survey: A Cohort Study to Evaluate the Safety of Cuvitru in Patients With Primary Immunodeficiency Using the PIDJ2 (Primary Immunodeficiency Database in Japan) Registry
Primary endpoint: Number of Participants Who Experience Anaphylactic Reaction as an Adverse Event (AE)
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Primary endpoint: Fetus/Neonate with Outcome of Death or Adjudicated Severe Bleeding or Platelet Count Less Than (<) 30*10^9/L
Phase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients With Guillain-Barré Syndrome.
Primary endpoint: Guillain-Barre Syndrome Disability Scale (GBS-DS)
An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing Persistent Neutralizing Antibodies
Primary endpoint: Rate of Anti-Idursulfase Antibodies Formation, Including Anti-Idursulfase Antibodies That Have Enzyme Neutralizing Activity
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
Primary endpoint: Cohort A: Treatment failure rate
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Primary endpoint: Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity
Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain
Primary endpoint: Length of vaso-occlusive crisis (VOC)
Frequently asked questions
Which companies have sourced relationships with immunoglobulin G?
immunoglobulin G has dated SEC/FDA relationship records for ADMA BIOLOGICS, INC..
How many clinical trials involve immunoglobulin G?
BioSniper tracks 9 clinical trials involving immunoglobulin G.